WebBackground: No randomized studies have compared low-dose or high-dose concurrent chemoradiotherapy (CRT). Methods: In this study, 7219 patients with stage III or IV head and neck squamous cell carcinoma (HNSCC) were enrolled and categorized into 2 groups: group 1, comprising those undergoing low-dose concurrent CRT (n = 1575), and group … WebSep 18, 2024 · NCBI Bookshelf
Cisplatin Cancer information Cancer Research UK
Webcombination of a cisplatin-based regimen and radiother-apy; in 49% of patients, single-agent cisplatin was used.4 The rationale for adding cisplatin to radiation therapy is based on its radiosensitizing properties and a toxicity pro-file not overlapping with radiotherapy. The National Comprehensive Cancer Network currently WebApr 4, 2024 · Cisplatin or carboplatin + paclitaxel + cetuximab 37,38 (non-nasopharyngeal) Day 1: Cisplatin 75 or 100mg/m 2 IV or carboplatin AUC 6mg·min/mL IV. Day 1: … inbursa heroes tecamac
Accelerated fractionation radiotherapy and late intensification with …
WebCisplatin is a chemotherapy drug. You might have it as a treatment for a number of different types of cancer. You might have cisplatin on its own or in combination with other cancer … WebAccelerated fractionation radiotherapy and late intensification with 2 ... WebBackground: Triweekly high-dose cisplatin (100 mg/m 2) with concurrent radiation therapy is the current standard of care in the definitive or appropriate postoperative setting in head and neck squamous cell carcinoma (HNSCC).We compared triweekly 100 mg/m 2 with alternative weekly 40 mg/m 2 and weekly <40 mg/m 2 cisplatin regimens.. Methods: … inburs lehigh